Enhancing Cervical Cancer Prevention in South African Women: Primary HPV mRNA Screening with Different Genotype Combinations
Preprint
- 27 October 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Cervical cancer prevention in regions with limited access to screening and HPV vaccination necessitates innovative approaches. This study explored the potential of a test-and-treat strategy using mRNA HPV tests to impact cervical cancer prevention in a high-prevalence HIV population. Methods: A cervical screening study was conducted at three South African hospitals involving 710 under-screened, non-pregnant women (25 to 65 years) without known cervical diseases. Cytology, HPV testing, colposcopy, and biopsies were performed concurrently. Histopathologists determined final histological diagnoses based on biopsy and LLETZ histology. mRNA-HPV-genotyping for 3 (16, 18, 45) to 8 (16, 18, 31, 33, 35, 45, 52, 58) high-risk types was performed on leftover liquid-based cytology material. The preventive potential of the test-and-treat approach was estimated based on published data, reporting the causative HPV types in cervical cancer tissue from South African women. Treatment was provided as needed. Results: HPV positivity rate more than doubled from 3-type (15.2%; 95% CI: 12.6-17.8) to 8-type mRNA (31.5%; 95% CI: 28.8-34.9) combinations, significantly higher among HIV-positive women. CIN3+ prevalence among HIV-positive women (26.4%) was double that of HIV-negative women (12.9%) (p<0.01). The 6-type combination showed the best balance of sensitivity, specificity and treatment group size, and effectiveness to prevent cervical cancer. A 4-type combination (16, 18, 35, 45) could potentially prevent 77.6% (95% CI: 71.2-84.0) of cervical cancer burden by treating 20% and detecting 41.1% of CIN3 cases in the study group. Similarly, a 6-type combination (16, 18, 31, 33, 35, 45), treating 25% and including 62% of CIN3 cases, might prevent 85% of cervical cancer cases (95% CI: 79.6-90.6) among HIV-positive and negative women. Conclusion: Employing mRNA HPV tests within a test-and-treat approach holds huge promise for targeted cervical cancer prevention in under-screened populations. Testing for mRNA of the 6 highest-risk HPV types in this population and treating them all is projected to effectively prevent progression from CIN3 to invasive cervical cancer while reducing overtreatment in resource-constrained settings.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?Journal of the American Society of Cytopathology, 2020
- Human papillomavirus prevalence and risk factors among HIV-negative and HIV-positive women residing in rural Eastern Cape, South AfricaInternational Journal of Infectious Diseases, 2020
- Primary HPV screening for cervical cancerBest Practice & Research Clinical Obstetrics & Gynaecology, 2020
- Reducing overtreatment associated with overdiagnosis in cervical cancer screening—A model‐based benefit–harm analysis for AustriaInternational Journal of Cancer, 2019
- The natural history of human papillomavirus infectionBest Practice & Research Clinical Obstetrics & Gynaecology, 2018
- HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian womenJournal of Medical Virology, 2015
- Triage of women with minor abnormal cervical cytology: Meta‐analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high‐risk human papillomavirus typesCancer Cytopathology, 2013
- Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancerInternational Journal of Cancer, 2012
- The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm ChangeArchives of Medical Research, 2009
- Cervical Cancer Prevention—Cervical Screening: Science in EvolutionObstetrics and Gynecology Clinics of North America, 2007